Sohini Das, Vinay Umarji And Virendra Singh Rawat

Stories by Sohini Das, Vinay Umarji And Virendra Singh Rawat

'APIs are a very strategic part of Biocon's business'

'APIs are a very strategic part of Biocon's business'

Rediff.com   7 Jan 2024

'There is no reason why we should break this business up.'

Trade generics growth to dent value expansion of domestic drug market

Trade generics growth to dent value expansion of domestic drug market

Rediff.com   2 Jan 2024

Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.

Hyderabad firm develops next-gen XBB1.5 Covid vax, awaits trial nod

Hyderabad firm develops next-gen XBB1.5 Covid vax, awaits trial nod

Rediff.com   28 Dec 2023

As of now, Gennova Biopharmaceuticals has launched a vaccine, Gemcovac-OM, which is based on the Omicron variant.

Does India have enough vaccine reserves to combat another Covid wave?

Does India have enough vaccine reserves to combat another Covid wave?

Rediff.com   27 Dec 2023

According to CoWIN data, only 73 vaccination centres are currently active in India, of which 32 are government-run.

Are hospitals ready to handle Covid surge?

Are hospitals ready to handle Covid surge?

Rediff.com   26 Dec 2023

Larger hospitals are not worried about a spike in cases, as they are now accustomed to converting ICUs and general wards into negative pressure zones or isolation rooms. For smaller hospitals, the task is tedious.

Medica + Manipal Will Overtake Apollo

Medica + Manipal Will Overtake Apollo

Rediff.com   12 Dec 2023

Next year Medica and Manipal will merge, making the amalgamated entity the largest corporate hospital chain in the country, overtaking Apollo Hospitals Enterprises.

Auto industry Q2 preview: Product mix, commodity tailwinds to aid margins

Auto industry Q2 preview: Product mix, commodity tailwinds to aid margins

Rediff.com   21 Oct 2023

Automobile manufacturers are likely to report strong numbers for the September quarter of Financial Year 2023-24 (Q2 FY24), riding on growth across segments and offset by a marginal drop in overall two-wheeler (2W) volumes. Higher average selling price (ASP) year-on-year (YoY), which was necessitated by price hikes taken by original equipment manufacturers (OEMs), and an improved product mix will also aid revenues and margins. Moreover, commodity prices are down on a YoY basis, leading to higher margins in earnings before interest, taxes, depreciation and amortisation (Ebitda).

Number of women in blue-collar jobs increasing across manufacturing sector

Number of women in blue-collar jobs increasing across manufacturing sector

Rediff.com   20 Oct 2023

"Lady candidates need not apply." So read the postscript in a job notice from Telco (now Tata Motors) on a notice board in the corridors of the Indian Institute of Science, Bangalore (now Bengaluru), in 1974. Irked, Sudha Murty, who was then pursuing her masters in computer science at the institute, wrote a postcard to JRD Tata, expressing her surprise at this gender discrimination, especially since the Tata Group were pioneers on many fronts. Shortly, Murty became the first woman on the firm's shop floor.

Nirma's new clothes: The journey of detergent brand towards healthcare

Nirma's new clothes: The journey of detergent brand towards healthcare

Rediff.com   12 Oct 2023

Nirma's tryst with the pharmaceutical space started in 2006 when it acquired the ailing Core Healthcare in a deal reported to be worth Rs 300 crore. The Ahmedabad-based manufacturer of intravenous fluids was subsequently renamed Nirlife. Pharma industry insiders say Nirma, which broke open the detergent market in the 1990s with low prices and massive advertising, tried an encore of the low-price strategy in pharma, but with mixed results.

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Rediff.com   3 Oct 2023

India's pharmaceutical exports to Iran have been hit owing to depleting rupee reserves in the West Asian country because of India stopping the import of crude oil from it in 2019 following US sanctions. Pharmaceutical exports dropped 71.25 per cent in April-August this year over the same period last year. The data from the Pharmaceutical Exports Promotion Council (Pharmexcil) showed exports to Iran had declined 31.29 per cent in 2022-23 as against the previous financial year.

Cipla deploys drones to fly in critical drugs

Cipla deploys drones to fly in critical drugs

Rediff.com   27 Sep 2023

Drug major Cipla on Tuesday said it has launched drone-powered deliveries of critical medicines - cardiac, respiratory and other essential chronic therapies - to hospitals and pharmacies across Himachal Pradesh in partnership with Skype Air Mobility, a Gurugram-based drone delivery company. Cipla is the first among large Indian pharmaceutical companies to adopt drone-based deliveries to facilitate expedited supply to stockists in remote areas, it claimed. The Mumbai-based firm said the use of drones will support the on-time delivery of its medicines to chemists and clinics in remote areas, and minimise risks of affecting cold chain products due to temperature excursions.

'Need to make Auto Exports a national mission'

'Need to make Auto Exports a national mission'

Rediff.com   26 Sep 2023

'There is a need for a national task force with a singular objective to increase automotive exports.'

Jeep To Drive Petrol Options For India

Jeep To Drive Petrol Options For India

Rediff.com   26 Sep 2023

The iconic brand is considering petrol powertrains for its entire Indian portfolio, which includes the Jeep Compass, Meridian, Grand Cherokee and Wrangler.

Govt in talks with SII for Nipah antibody, may put imports on hold

Govt in talks with SII for Nipah antibody, may put imports on hold

Rediff.com   21 Sep 2023

Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.

Rice Economy Faces Turmoil as El Nino Turns Up Heat

Rice Economy Faces Turmoil as El Nino Turns Up Heat

Rediff.com   15 Sep 2023

In the coming months, globally as well as in India, rice might remain a hot potato.

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Rediff.com   14 Sep 2023

As the market buzzes with news of Cipla promoters exiting the business through a stake sale and Ahmedabad-based Mehta family-led Torrent Pharmaceuticals racing to acquire its rival, Cipla, an analysis reveals that if the deal were to go through, both companies might need to divest as many as 15 brands to comply with Competition Commission of India (CCI) norms. A recent analysis by Bernstein shows that Cipla and Torrent share a presence in 332 products (based on product and molecule data from market research firm IQVIA). Bernstein analysts Nithya Balasubramanian and Parth Shah noted that, while this may appear as a high number, a significant portion of these products lack significance.

India's pharma industry likely to take 5-6% price hikes this year

India's pharma industry likely to take 5-6% price hikes this year

Rediff.com   6 Sep 2023

Notwithstanding the fact that the country's pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential Medicines (NLEM) in 2023, analysts and industry insiders predict that the overall domestic pharma industry will only witness a price hike of 5-6 per cent. This is attributed to higher competitive intensity in the market. Krishnakumar V, executive director and chief operating officer (CEO) of Eris Lifesciences, a domestic-focused pharma company, noted that the NLEM segment experienced growth suppression of around 150 basis points due to price reductions during the January to July period this year.

From hatchbacks to holidays, consumers ready to loosen purse strings

From hatchbacks to holidays, consumers ready to loosen purse strings

Rediff.com   1 Sep 2023

With Onam and Raksha Bandhan just around the corner, the festival season is ready to kick off in full swing. As people embrace the celebratory spirit, companies anticipate a surge in sales this year. Consumer durables firms are expecting strong growth of 40-50 per cent in the premium segment during the upcoming season. Appliance makers also foresee increased demand for cooling appliances - refrigerators and air conditioners - which were impacted by unseasonal rainfall.

47,000 Luxury Cars To Be Sold This Year!

47,000 Luxury Cars To Be Sold This Year!

Rediff.com   28 Aug 2023

After a brief lull during the pandemic, there is a strong revival in luxury car sales, bolstered by more launches across price bands, replacement demand, ban on old diesel vehicles in the NCR, and 'revenge buying'.

Why All Is Not Well In Bharat Gears Family

Why All Is Not Well In Bharat Gears Family

Rediff.com   26 Aug 2023

The sons learned that they had been completely disinherited and that Surinder Kanwar's new wife would inherit everything.